Aberdeen Group
AMLX icon

Aberdeen Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Aberdeen Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Buy
+737,670
New +$11.4M 0.02% 544
2025
Q3 		– Sell
-738,657
Closed -$4.73M – 953
2025
Q2 		$4.73M Sell
738,657
-1,691,701
-70% -$8.23M 0.01% 710
2025
Q1 		$8.6M Buy
2,430,358
+707,553
+41% +$2.52M 0.02% 595
2024
Q4 		$6.51M Sell
1,722,805
-249,437
-13% -$1.17M 0.01% 600
2024
Q3 		$6.39M Buy
1,972,242
+1,853,995
+1,568% +$4.17M 0.01% 607
2024
Q2 		$225K Hold
118,247
– – ﹤0.01% 918
2024
Q1 		$336K Sell
118,247
-77,246
-40% -$1.01M ﹤0.01% 892
2023
Q4 		$2.88M Buy
+195,493
New +$3M 0.01% 746

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Aberdeen Group's AMLX Position: Q2 2026 in Review

Aberdeen Group opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 737,670 shares worth $13.2M. The stake represents 0.02% of the portfolio and ranks #544 among its holdings. This is a return to the name: Aberdeen Group previously reported a position in AMLX as recently as Q2 2025.

Aberdeen Group first reported a position in AMLX in Q4 2023 and has held it in 8 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Aberdeen Group held 737,670 shares of Amylyx Pharmaceuticals worth $13.2M as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Aberdeen Group position in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.02% of Aberdeen Group's portfolio in Q2 2026, its #544 holding.
  • Aberdeen Group first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.